Strategic Update & Teleconference Call Notification
Filed with ASX · · 28 pages · English
Sydney, 21 April 2021. Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to provide a strategic update and release a corporate investor presentation. Actinogen’s Chief Executive Officer and Managing Director, Dr Steven Gourlay, will be hosting a teleconference on Friday, 23 April 2021 at 9.00am AEST. This teleconference will be used to update existing shareholders, potential investors
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen CEO assumes Managing Director position
- Actinogen appoints Dr Steven Gourlay as CEO
- ACW raises an addtional $3.55m under a Shortfall Placement
- Resignation of Dr Bill Ketelbey as Chief Executive Officer
- FDA Grants ACW Rare Paediatric Disease Designation in FXS
Later from Actinogen Medical
- Response to ASX Price Query
- Actinogen Ethics Committee approval for XanaMIA study
- Clinical progress for XanaMIA trial
- Actinogen receives positive Pre-IND FDA advice for FXS
- First Patient Enrolled in XanaMIA trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical